COMPANY

PeproMene Bio

HQ: Irvine, CA source · pepromenebio.com ↗

Keywords: oncology antibody CAR-T immunology autoimmune diseases cancer Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma BAFFR-CAR T cells

Location: Irvine, CA · source · Oct 12, 2026

Profile checked Oct 10, 2026

$11.0MRaised (2 yrs)2Trials (company is sponsor)

Timeline

Dec 19, 2024 Raise Private equity round: $11M (total, as published), announced Dec 19, 2024. Source: company's own press page. source ↗
Jun 13, 2022 Trial start Phase 1: BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL source ↗
May 18, 2021 Trial start Phase 1: BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL source ↗

Upcoming milestones

Nov 18, 2026 (ESTIMATED) · Phase 1 · BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL · NCT04690595
Jul 13, 2027 (ESTIMATED) · Phase 1 · BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL · NCT05370430

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $11.0M. Last 2 years.

Dec 19, 2024 Private equity round: $11M (total, as published), announced Dec 19, 2024. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04690595	BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL	Phase 1	Active, not recruiting	May 18, 2021	Nov 18, 2026 (estimated)
NCT05370430	BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL	Phase 1	Recruiting	Jun 13, 2022	Jul 13, 2027 (estimated)